Given the role of insulin resistance and metabolic alterations in NAFLD, it is important to understand the role of FXR in the different metabolic organs to anticipate potential metabolic side effects in light of the clinical development of FXR agonists for NASH and fibrosis. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.